Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)
Safety and Efficacy pf Propionyl-L-Carnitine in Combination With Monitored Exercise Training in Peripheral Arterial Disease (Intermittent Claudication).
  • Phase

    Phase 3
  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

Patients with peripheral artery disease have decreased blood flow to exercising muscle causing pain. This decreased blood flow to the muscle affects the level of acylcarnitines which in turn decreases the level of carnitine. Carnitine allows muscles to function properly. This study will test the safety and efficacy of Propionyl-L-Carnitine taken in combination with a monitored exercise training program.
To test the hypothesis that Propionyl-L-Carnitine taken in combination with monitored exercise training may improve exercise performance the study will randomize male or female adults with peripheral artery disease and claudication to receive either Proprionyl-L-Carnitine or Placebo.
Study Started
Apr 30
Primary Completion
Mar 31
Study Completion
Mar 31
Last Update
Aug 25

Drug Propionyl-L-Carnitine

2 grams per day for six months

Drug PLC

2 grams/day for six months

PLC Experimental

Investigational drug

Placebo Placebo Comparator


Inclusion Criteria:

Ambulatory outpatient who are able to exercise
Intermittent claudication due to peripheral artery disease
Willingness to participate in a monitored exercise training program

Exclusion Criteria:

Pain at rest, ischemic ulcerations, gangrene of the lower extremity
Peripheral Artery Disease of a non-atherosclerotic nature
Any disease process other than PAD, that may interfere with performance during the treadmill test or prevent the subject from reaching their claudication-limited PWT
Current participation in an exercise training program or previous participtation in a monitored exercise training program within 6 months of the screening visit.
No Results Posted